Abstract: Methods and systems to identify collaborative communities of individuals from graphs of multiple types of relationships amongst the individuals, including to mine data related to multiple types of relationships amongst individuals, construct graphs to represent the respective types of relationships amongst individuals, and perform a multiplex graph convolutional network (MGCN) artificial intelligence machine learning (AIML) analysis across the multiple graphs to identify the collaborative communities. A mathematical representation of the graphs may be learned/tuned to optimize clustering of the individuals. Multiple parameters (inter-graph weights, consensus regularization function) may be jointly tuned based on a joint optimization function. The collaborative communities may be displayed such that relative positions of the individuals represent measures of influence exerted by the respective individuals within the respective collaborative communities.

Abstract: Embodiments of the present disclosure provide a method for identifying those entities within a network that have the most influence on other entities within the network. A multi-relational network comprising links among a plurality of physicians is generated based on peer network data, wherein each link indicates a first physician that influences a second physician, and a weight of the influence. A decision by a treating physician of the plurality of physicians is decomposed, using a deep learning engine, into a magnitude of peer influence and a magnitude of control factor influence based on the multi-relational network and a plurality of control factors respectively. The magnitude of peer influence among one or more physicians in the multi-relational network is distributed among physicians in the multi-relational network based on the links each physician maintains with other physicians.

Abstract: Methods and systems to identify collaborative communities of individuals from graphs of multiple types of relationships amongst the individuals, including to mine data related to multiple types of relationships amongst individuals, construct graphs to represent the respective types of relationships amongst individuals, and perform a multiplex graph convolutional network (MGCN) artificial intelligence machine learning (AIML) analysis across the multiple graphs to identify the collaborative communities. A mathematical representation of the graphs may be learned/tuned to optimize clustering of the individuals. Multiple parameters (inter-graph weights, consensus regularization function) may be jointly tuned based on a joint optimization function. The collaborative communities may be displayed such that relative positions of the individuals represent measures of influence exerted by the respective individuals within the respective collaborative communities.

Abstract: Embodiments of the present disclosure provide a method for identifying those entities within a network that have the most influence on other entities within the network. A multi-relational network comprising links among a plurality of physicians is generated based on peer network data, wherein each link indicates a first physician that influences a second physician, and a weight of the influence. A decision by a treating physician of the plurality of physicians is decomposed, using a deep learning engine, into a magnitude of peer influence and a magnitude of control factor influence based on the multi-relational network and a plurality of control factors respectively. The magnitude of peer influence among one or more physicians in the multi-relational network is distributed among physicians in the multi-relational network based on the links each physician maintains with other physicians.

Abstract: Systems and techniques are disclosed for using machine-learning to identify potential opportunity patients that are more likely to adjust his/her preference for a healthcare provider or service. In some implementations, integrated patient data is obtained. A patient sequence feature vector, a provider sequence feature vector, and a set of entity-specific feature vectors are generated. A set of opportunity patients is identified. A notification is transmitted to the set of opportunity patients about a second treatment plan.

Abstract: The present invention provides for compounds of formula (I) wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.